KR101818499B1 - Antibiotic composition with novel endolysin LysSA97 from Staphylococcus aureus bacteriophage and compound from essential oil - Google Patents
Antibiotic composition with novel endolysin LysSA97 from Staphylococcus aureus bacteriophage and compound from essential oil Download PDFInfo
- Publication number
- KR101818499B1 KR101818499B1 KR1020160113589A KR20160113589A KR101818499B1 KR 101818499 B1 KR101818499 B1 KR 101818499B1 KR 1020160113589 A KR1020160113589 A KR 1020160113589A KR 20160113589 A KR20160113589 A KR 20160113589A KR 101818499 B1 KR101818499 B1 KR 101818499B1
- Authority
- KR
- South Korea
- Prior art keywords
- lyssa97
- staphylococcus aureus
- endorhysin
- essential oil
- gly
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 36
- 241000191967 Staphylococcus aureus Species 0.000 title claims description 51
- 239000000341 volatile oil Substances 0.000 title abstract description 16
- KDXKERNSBIXSRK-UHFFFAOYSA-N lysine Chemical compound NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 title abstract description 15
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 title abstract description 12
- 230000003115 biocidal effect Effects 0.000 title abstract description 3
- 150000001875 compounds Chemical class 0.000 title description 9
- 241001515965 unidentified phage Species 0.000 title description 9
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 claims description 40
- 239000005844 Thymol Substances 0.000 claims description 20
- 229960000790 thymol Drugs 0.000 claims description 20
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 claims description 18
- 229940117916 cinnamic aldehyde Drugs 0.000 claims description 18
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 claims description 18
- RECUKUPTGUEGMW-UHFFFAOYSA-N carvacrol Chemical compound CC(C)C1=CC=C(C)C(O)=C1 RECUKUPTGUEGMW-UHFFFAOYSA-N 0.000 claims description 17
- HHTWOMMSBMNRKP-UHFFFAOYSA-N carvacrol Natural products CC(=C)C1=CC=C(C)C(O)=C1 HHTWOMMSBMNRKP-UHFFFAOYSA-N 0.000 claims description 17
- 235000007746 carvacrol Nutrition 0.000 claims description 17
- WYXXLXHHWYNKJF-UHFFFAOYSA-N isocarvacrol Natural products CC(C)C1=CC=C(O)C(C)=C1 WYXXLXHHWYNKJF-UHFFFAOYSA-N 0.000 claims description 17
- 230000002147 killing effect Effects 0.000 claims description 17
- 235000013305 food Nutrition 0.000 claims description 15
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 9
- 235000013373 food additive Nutrition 0.000 claims description 6
- 239000002778 food additive Substances 0.000 claims description 6
- 230000002124 endocrine Effects 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 3
- 238000011109 contamination Methods 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 230000000694 effects Effects 0.000 abstract description 13
- 230000001954 sterilising effect Effects 0.000 abstract description 9
- 239000003242 anti bacterial agent Substances 0.000 abstract description 6
- 238000004659 sterilization and disinfection Methods 0.000 abstract description 6
- 238000011284 combination treatment Methods 0.000 abstract description 4
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 39
- 238000011282 treatment Methods 0.000 description 25
- 238000002835 absorbance Methods 0.000 description 19
- 241000894006 Bacteria Species 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 239000000126 substance Substances 0.000 description 10
- 229960004484 carbachol Drugs 0.000 description 9
- 230000002101 lytic effect Effects 0.000 description 8
- 235000013336 milk Nutrition 0.000 description 8
- 239000008267 milk Substances 0.000 description 8
- 210000004080 milk Anatomy 0.000 description 8
- 150000001413 amino acids Chemical group 0.000 description 7
- 239000003921 oil Substances 0.000 description 5
- 206010016952 Food poisoning Diseases 0.000 description 4
- 208000019331 Foodborne disease Diseases 0.000 description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 235000015278 beef Nutrition 0.000 description 4
- 241000823609 Staphylococcus aureus subsp. aureus RN4220 Species 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- BJJRNAVDQGREGC-HOUAVDHOSA-N Thr-Trp-Asn Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(=O)N)C(=O)O)N)O BJJRNAVDQGREGC-HOUAVDHOSA-N 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- FSXRLASFHBWESK-UHFFFAOYSA-N dipeptide phenylalanyl-tyrosine Natural products C=1C=C(O)C=CC=1CC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FSXRLASFHBWESK-UHFFFAOYSA-N 0.000 description 2
- 108010015792 glycyllysine Proteins 0.000 description 2
- 235000013622 meat product Nutrition 0.000 description 2
- 229960003471 retinol Drugs 0.000 description 2
- 235000020944 retinol Nutrition 0.000 description 2
- 239000011607 retinol Substances 0.000 description 2
- 108010026333 seryl-proline Proteins 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 108010017949 tyrosyl-glycyl-glycine Proteins 0.000 description 2
- 108010073969 valyllysine Proteins 0.000 description 2
- ZEXDYVGDZJBRMO-ACZMJKKPSA-N Ala-Asn-Gln Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N ZEXDYVGDZJBRMO-ACZMJKKPSA-N 0.000 description 1
- WXERCAHAIKMTKX-ZLUOBGJFSA-N Ala-Asp-Asp Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O WXERCAHAIKMTKX-ZLUOBGJFSA-N 0.000 description 1
- IFKQPMZRDQZSHI-GHCJXIJMSA-N Ala-Ile-Asn Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(O)=O IFKQPMZRDQZSHI-GHCJXIJMSA-N 0.000 description 1
- OYJCVIGKMXUVKB-GARJFASQSA-N Ala-Leu-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N OYJCVIGKMXUVKB-GARJFASQSA-N 0.000 description 1
- MFMDKJIPHSWSBM-GUBZILKMSA-N Ala-Lys-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O MFMDKJIPHSWSBM-GUBZILKMSA-N 0.000 description 1
- NCQMBSJGJMYKCK-ZLUOBGJFSA-N Ala-Ser-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O NCQMBSJGJMYKCK-ZLUOBGJFSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- TTXYKSADPSNOIF-IHRRRGAJSA-N Arg-Asp-Phe Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O TTXYKSADPSNOIF-IHRRRGAJSA-N 0.000 description 1
- PBSOQGZLPFVXPU-YUMQZZPRSA-N Arg-Glu-Gly Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O PBSOQGZLPFVXPU-YUMQZZPRSA-N 0.000 description 1
- LXMKTIZAGIBQRX-HRCADAONSA-N Arg-Phe-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O LXMKTIZAGIBQRX-HRCADAONSA-N 0.000 description 1
- YFHATWYGAAXQCF-JYJNAYRXSA-N Arg-Pro-Phe Chemical compound NC(N)=NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 YFHATWYGAAXQCF-JYJNAYRXSA-N 0.000 description 1
- KXOPYFNQLVUOAQ-FXQIFTODSA-N Arg-Ser-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O KXOPYFNQLVUOAQ-FXQIFTODSA-N 0.000 description 1
- KSHJMDSNSKDJPU-QTKMDUPCSA-N Arg-Thr-His Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 KSHJMDSNSKDJPU-QTKMDUPCSA-N 0.000 description 1
- ISVACHFCVRKIDG-SRVKXCTJSA-N Arg-Val-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O ISVACHFCVRKIDG-SRVKXCTJSA-N 0.000 description 1
- SWLOHUMCUDRTCL-ZLUOBGJFSA-N Asn-Ala-Asn Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N SWLOHUMCUDRTCL-ZLUOBGJFSA-N 0.000 description 1
- QQEWINYJRFBLNN-DLOVCJGASA-N Asn-Ala-Phe Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 QQEWINYJRFBLNN-DLOVCJGASA-N 0.000 description 1
- DQTIWTULBGLJBL-DCAQKATOSA-N Asn-Arg-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(=O)N)N DQTIWTULBGLJBL-DCAQKATOSA-N 0.000 description 1
- NVGWESORMHFISY-SRVKXCTJSA-N Asn-Asn-Phe Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O NVGWESORMHFISY-SRVKXCTJSA-N 0.000 description 1
- ZKDGORKGHPCZOV-DCAQKATOSA-N Asn-His-Arg Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N ZKDGORKGHPCZOV-DCAQKATOSA-N 0.000 description 1
- YYSYDIYQTUPNQQ-SXTJYALSSA-N Asn-Ile-Ile Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O YYSYDIYQTUPNQQ-SXTJYALSSA-N 0.000 description 1
- ORJQQZIXTOYGGH-SRVKXCTJSA-N Asn-Lys-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O ORJQQZIXTOYGGH-SRVKXCTJSA-N 0.000 description 1
- YRTOMUMWSTUQAX-FXQIFTODSA-N Asn-Pro-Asp Chemical compound NC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O YRTOMUMWSTUQAX-FXQIFTODSA-N 0.000 description 1
- YUOXLJYVSZYPBJ-CIUDSAMLSA-N Asn-Pro-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O YUOXLJYVSZYPBJ-CIUDSAMLSA-N 0.000 description 1
- BCADFFUQHIMQAA-KKHAAJSZSA-N Asn-Thr-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O BCADFFUQHIMQAA-KKHAAJSZSA-N 0.000 description 1
- RDLYUKRPEJERMM-XIRDDKMYSA-N Asn-Trp-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(O)=O RDLYUKRPEJERMM-XIRDDKMYSA-N 0.000 description 1
- QIRJQYQOIKBPBZ-IHRRRGAJSA-N Asn-Tyr-Arg Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O QIRJQYQOIKBPBZ-IHRRRGAJSA-N 0.000 description 1
- YSYTWUMRHSFODC-QWRGUYRKSA-N Asn-Tyr-Gly Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(O)=O YSYTWUMRHSFODC-QWRGUYRKSA-N 0.000 description 1
- BEHQTVDBCLSCBY-CFMVVWHZSA-N Asn-Tyr-Ile Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O BEHQTVDBCLSCBY-CFMVVWHZSA-N 0.000 description 1
- SPKCGKRUYKMDHP-GUDRVLHUSA-N Asp-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(=O)O)N SPKCGKRUYKMDHP-GUDRVLHUSA-N 0.000 description 1
- UJGRZQYSNYTCAX-SRVKXCTJSA-N Asp-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(O)=O UJGRZQYSNYTCAX-SRVKXCTJSA-N 0.000 description 1
- LIVXPXUVXFRWNY-CIUDSAMLSA-N Asp-Lys-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O LIVXPXUVXFRWNY-CIUDSAMLSA-N 0.000 description 1
- HJCGDIGVVWETRO-ZPFDUUQYSA-N Asp-Lys-Ile Chemical compound CC[C@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC(O)=O)C(O)=O HJCGDIGVVWETRO-ZPFDUUQYSA-N 0.000 description 1
- USNJAPJZSGTTPX-XVSYOHENSA-N Asp-Phe-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O USNJAPJZSGTTPX-XVSYOHENSA-N 0.000 description 1
- HICVMZCGVFKTPM-BQBZGAKWSA-N Asp-Pro-Gly Chemical compound OC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O HICVMZCGVFKTPM-BQBZGAKWSA-N 0.000 description 1
- KNOGLZBISUBTFW-QRTARXTBSA-N Asp-Trp-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](C(C)C)C(O)=O KNOGLZBISUBTFW-QRTARXTBSA-N 0.000 description 1
- CPMKYMGGYUFOHS-FSPLSTOPSA-N Asp-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CC(O)=O CPMKYMGGYUFOHS-FSPLSTOPSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- LHLSSZYQFUNWRZ-NAKRPEOUSA-N Cys-Arg-Ile Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O LHLSSZYQFUNWRZ-NAKRPEOUSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- XEYMBRRKIFYQMF-GUBZILKMSA-N Gln-Asp-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O XEYMBRRKIFYQMF-GUBZILKMSA-N 0.000 description 1
- SDSMVVSHLAAOJL-UKJIMTQDSA-N Gln-Val-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)N)N SDSMVVSHLAAOJL-UKJIMTQDSA-N 0.000 description 1
- FYBSCGZLICNOBA-XQXXSGGOSA-N Glu-Ala-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O FYBSCGZLICNOBA-XQXXSGGOSA-N 0.000 description 1
- YYOBUPFZLKQUAX-FXQIFTODSA-N Glu-Asn-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O YYOBUPFZLKQUAX-FXQIFTODSA-N 0.000 description 1
- JRCUFCXYZLPSDZ-ACZMJKKPSA-N Glu-Asp-Ser Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O JRCUFCXYZLPSDZ-ACZMJKKPSA-N 0.000 description 1
- LVCHEMOPBORRLB-DCAQKATOSA-N Glu-Gln-Lys Chemical compound NCCCC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCC(O)=O)C(O)=O LVCHEMOPBORRLB-DCAQKATOSA-N 0.000 description 1
- AQNYKMCFCCZEEL-JYJNAYRXSA-N Glu-Lys-Tyr Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 AQNYKMCFCCZEEL-JYJNAYRXSA-N 0.000 description 1
- DMYACXMQUABZIQ-NRPADANISA-N Glu-Ser-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O DMYACXMQUABZIQ-NRPADANISA-N 0.000 description 1
- ZQNCUVODKOBSSO-XEGUGMAKSA-N Glu-Trp-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](C)C(O)=O ZQNCUVODKOBSSO-XEGUGMAKSA-N 0.000 description 1
- PYTZFYUXZZHOAD-WHFBIAKZSA-N Gly-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)CN PYTZFYUXZZHOAD-WHFBIAKZSA-N 0.000 description 1
- RQZGFWKQLPJOEQ-YUMQZZPRSA-N Gly-Arg-Gln Chemical compound C(C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)CN)CN=C(N)N RQZGFWKQLPJOEQ-YUMQZZPRSA-N 0.000 description 1
- FMNHBTKMRFVGRO-FOHZUACHSA-N Gly-Asn-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CN FMNHBTKMRFVGRO-FOHZUACHSA-N 0.000 description 1
- LURCIJSJAKFCRO-QWRGUYRKSA-N Gly-Asn-Tyr Chemical compound [H]NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O LURCIJSJAKFCRO-QWRGUYRKSA-N 0.000 description 1
- MQVNVZUEPUIAFA-WDSKDSINSA-N Gly-Cys-Gln Chemical compound C(CC(=O)N)[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)CN MQVNVZUEPUIAFA-WDSKDSINSA-N 0.000 description 1
- DTRUBYPMMVPQPD-YUMQZZPRSA-N Gly-Gln-Arg Chemical compound [H]NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O DTRUBYPMMVPQPD-YUMQZZPRSA-N 0.000 description 1
- CCQOOWAONKGYKQ-BYPYZUCNSA-N Gly-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)CN CCQOOWAONKGYKQ-BYPYZUCNSA-N 0.000 description 1
- INLIXXRWNUKVCF-JTQLQIEISA-N Gly-Gly-Tyr Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 INLIXXRWNUKVCF-JTQLQIEISA-N 0.000 description 1
- ALOBJFDJTMQQPW-ONGXEEELSA-N Gly-His-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)CN ALOBJFDJTMQQPW-ONGXEEELSA-N 0.000 description 1
- COVXELOAORHTND-LSJOCFKGSA-N Gly-Ile-Val Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(O)=O COVXELOAORHTND-LSJOCFKGSA-N 0.000 description 1
- LHYJCVCQPWRMKZ-WEDXCCLWSA-N Gly-Leu-Thr Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LHYJCVCQPWRMKZ-WEDXCCLWSA-N 0.000 description 1
- MDKCBHZLQJZOCJ-STQMWFEESA-N Gly-Met-Tyr Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)NC(=O)CN MDKCBHZLQJZOCJ-STQMWFEESA-N 0.000 description 1
- HUFUVTYGPOUCBN-MBLNEYKQSA-N Gly-Thr-Ile Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O HUFUVTYGPOUCBN-MBLNEYKQSA-N 0.000 description 1
- GNNJKUYDWFIBTK-QWRGUYRKSA-N Gly-Tyr-Asp Chemical compound [H]NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O GNNJKUYDWFIBTK-QWRGUYRKSA-N 0.000 description 1
- JYGYNWYVKXENNE-OALUTQOASA-N Gly-Tyr-Trp Chemical compound [H]NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O JYGYNWYVKXENNE-OALUTQOASA-N 0.000 description 1
- AFMOTCMSEBITOE-YEPSODPASA-N Gly-Val-Thr Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O AFMOTCMSEBITOE-YEPSODPASA-N 0.000 description 1
- PGTISAJTWZPFGN-PEXQALLHSA-N His-Gly-Ile Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(O)=O PGTISAJTWZPFGN-PEXQALLHSA-N 0.000 description 1
- VFBZWZXKCVBTJR-SRVKXCTJSA-N His-Leu-Asp Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CC1=CN=CN1)N VFBZWZXKCVBTJR-SRVKXCTJSA-N 0.000 description 1
- QLBXWYXMLHAREM-PYJNHQTQSA-N His-Val-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC1=CN=CN1)N QLBXWYXMLHAREM-PYJNHQTQSA-N 0.000 description 1
- JRHFQUPIZOYKQP-KBIXCLLPSA-N Ile-Ala-Glu Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCC(O)=O JRHFQUPIZOYKQP-KBIXCLLPSA-N 0.000 description 1
- DMHGKBGOUAJRHU-UHFFFAOYSA-N Ile-Arg-Pro Natural products CCC(C)C(N)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(O)=O DMHGKBGOUAJRHU-UHFFFAOYSA-N 0.000 description 1
- RPZFUIQVAPZLRH-GHCJXIJMSA-N Ile-Asp-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)O)N RPZFUIQVAPZLRH-GHCJXIJMSA-N 0.000 description 1
- FUOYNOXRWPJPAN-QEWYBTABSA-N Ile-Glu-Phe Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N FUOYNOXRWPJPAN-QEWYBTABSA-N 0.000 description 1
- HUORUFRRJHELPD-MNXVOIDGSA-N Ile-Leu-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N HUORUFRRJHELPD-MNXVOIDGSA-N 0.000 description 1
- OVDKXUDMKXAZIV-ZPFDUUQYSA-N Ile-Lys-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)O)N OVDKXUDMKXAZIV-ZPFDUUQYSA-N 0.000 description 1
- YKZAMJXNJUWFIK-JBDRJPRFSA-N Ile-Ser-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)O)N YKZAMJXNJUWFIK-JBDRJPRFSA-N 0.000 description 1
- JZNVOBUNTWNZPW-GHCJXIJMSA-N Ile-Ser-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)O)N JZNVOBUNTWNZPW-GHCJXIJMSA-N 0.000 description 1
- WCNWGAUZWWSYDG-SVSWQMSJSA-N Ile-Thr-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)O)N WCNWGAUZWWSYDG-SVSWQMSJSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- LHSGPCFBGJHPCY-UHFFFAOYSA-N L-leucine-L-tyrosine Natural products CC(C)CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 LHSGPCFBGJHPCY-UHFFFAOYSA-N 0.000 description 1
- 241000880493 Leptailurus serval Species 0.000 description 1
- JKGHDYGZRDWHGA-SRVKXCTJSA-N Leu-Asn-Leu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O JKGHDYGZRDWHGA-SRVKXCTJSA-N 0.000 description 1
- MYGQXVYRZMKRDB-SRVKXCTJSA-N Leu-Asp-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN MYGQXVYRZMKRDB-SRVKXCTJSA-N 0.000 description 1
- PVMPDMIKUVNOBD-CIUDSAMLSA-N Leu-Asp-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O PVMPDMIKUVNOBD-CIUDSAMLSA-N 0.000 description 1
- NEEOBPIXKWSBRF-IUCAKERBSA-N Leu-Glu-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O NEEOBPIXKWSBRF-IUCAKERBSA-N 0.000 description 1
- KEVYYIMVELOXCT-KBPBESRZSA-N Leu-Gly-Phe Chemical compound CC(C)C[C@H]([NH3+])C(=O)NCC(=O)N[C@H](C([O-])=O)CC1=CC=CC=C1 KEVYYIMVELOXCT-KBPBESRZSA-N 0.000 description 1
- HGFGEMSVBMCFKK-MNXVOIDGSA-N Leu-Ile-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(O)=O HGFGEMSVBMCFKK-MNXVOIDGSA-N 0.000 description 1
- BRTVHXHCUSXYRI-CIUDSAMLSA-N Leu-Ser-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O BRTVHXHCUSXYRI-CIUDSAMLSA-N 0.000 description 1
- WFCKERTZVCQXKH-KBPBESRZSA-N Leu-Tyr-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(O)=O WFCKERTZVCQXKH-KBPBESRZSA-N 0.000 description 1
- NFLFJGGKOHYZJF-BJDJZHNGSA-N Lys-Ala-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN NFLFJGGKOHYZJF-BJDJZHNGSA-N 0.000 description 1
- YRWCPXOFBKTCFY-NUTKFTJISA-N Lys-Ala-Trp Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CCCCN)N YRWCPXOFBKTCFY-NUTKFTJISA-N 0.000 description 1
- ABHIXYDMILIUKV-CIUDSAMLSA-N Lys-Asn-Asn Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O ABHIXYDMILIUKV-CIUDSAMLSA-N 0.000 description 1
- IWWMPCPLFXFBAF-SRVKXCTJSA-N Lys-Asp-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O IWWMPCPLFXFBAF-SRVKXCTJSA-N 0.000 description 1
- NTBFKPBULZGXQL-KKUMJFAQSA-N Lys-Asp-Tyr Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 NTBFKPBULZGXQL-KKUMJFAQSA-N 0.000 description 1
- GGNOBVSOZPHLCE-GUBZILKMSA-N Lys-Gln-Asp Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O GGNOBVSOZPHLCE-GUBZILKMSA-N 0.000 description 1
- NKKFVJRLCCUJNA-QWRGUYRKSA-N Lys-Gly-Lys Chemical compound NCCCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCCN NKKFVJRLCCUJNA-QWRGUYRKSA-N 0.000 description 1
- HAUUXTXKJNVIFY-ONGXEEELSA-N Lys-Gly-Val Chemical compound [H]N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O HAUUXTXKJNVIFY-ONGXEEELSA-N 0.000 description 1
- MXMDJEJWERYPMO-XUXIUFHCSA-N Lys-Ile-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O MXMDJEJWERYPMO-XUXIUFHCSA-N 0.000 description 1
- CBNMHRCLYBJIIZ-XUXIUFHCSA-N Lys-Ile-Met Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](CCCCN)N CBNMHRCLYBJIIZ-XUXIUFHCSA-N 0.000 description 1
- WRODMZBHNNPRLN-SRVKXCTJSA-N Lys-Leu-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O WRODMZBHNNPRLN-SRVKXCTJSA-N 0.000 description 1
- ALGGDNMLQNFVIZ-SRVKXCTJSA-N Lys-Lys-Asp Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)O)N ALGGDNMLQNFVIZ-SRVKXCTJSA-N 0.000 description 1
- TWPCWKVOZDUYAA-KKUMJFAQSA-N Lys-Phe-Asp Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O TWPCWKVOZDUYAA-KKUMJFAQSA-N 0.000 description 1
- PLOUVAYOMTYJRG-JXUBOQSCSA-N Lys-Thr-Ala Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O PLOUVAYOMTYJRG-JXUBOQSCSA-N 0.000 description 1
- XATKLFSXFINPSB-JYJNAYRXSA-N Lys-Tyr-Gln Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(O)=O XATKLFSXFINPSB-JYJNAYRXSA-N 0.000 description 1
- MIMXMVDLMDMOJD-BZSNNMDCSA-N Lys-Tyr-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O MIMXMVDLMDMOJD-BZSNNMDCSA-N 0.000 description 1
- NHXXGBXJTLRGJI-GUBZILKMSA-N Met-Pro-Ser Chemical compound [H]N[C@@H](CCSC)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O NHXXGBXJTLRGJI-GUBZILKMSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 1
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 1
- 108010047562 NGR peptide Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- HXSUFWQYLPKEHF-IHRRRGAJSA-N Phe-Asn-Arg Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N HXSUFWQYLPKEHF-IHRRRGAJSA-N 0.000 description 1
- SWZKMTDPQXLQRD-XVSYOHENSA-N Phe-Asp-Thr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SWZKMTDPQXLQRD-XVSYOHENSA-N 0.000 description 1
- FKFCKDROTNIVSO-JYJNAYRXSA-N Phe-Pro-Met Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(O)=O FKFCKDROTNIVSO-JYJNAYRXSA-N 0.000 description 1
- PTDAGKJHZBGDKD-OEAJRASXSA-N Phe-Thr-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N)O PTDAGKJHZBGDKD-OEAJRASXSA-N 0.000 description 1
- 206010067268 Post procedural infection Diseases 0.000 description 1
- BNBBNGZZKQUWCD-IUCAKERBSA-N Pro-Arg-Gly Chemical compound NC(N)=NCCC[C@@H](C(=O)NCC(O)=O)NC(=O)[C@@H]1CCCN1 BNBBNGZZKQUWCD-IUCAKERBSA-N 0.000 description 1
- ORPZXBQTEHINPB-SRVKXCTJSA-N Pro-Arg-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1)C(O)=O ORPZXBQTEHINPB-SRVKXCTJSA-N 0.000 description 1
- GDXZRWYXJSGWIV-GMOBBJLQSA-N Pro-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H]1CCCN1 GDXZRWYXJSGWIV-GMOBBJLQSA-N 0.000 description 1
- JFNPBBOGGNMSRX-CIUDSAMLSA-N Pro-Gln-Ala Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O JFNPBBOGGNMSRX-CIUDSAMLSA-N 0.000 description 1
- RFWXYTJSVDUBBZ-DCAQKATOSA-N Pro-Pro-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 RFWXYTJSVDUBBZ-DCAQKATOSA-N 0.000 description 1
- POQFNPILEQEODH-FXQIFTODSA-N Pro-Ser-Ala Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O POQFNPILEQEODH-FXQIFTODSA-N 0.000 description 1
- MKGIILKDUGDRRO-FXQIFTODSA-N Pro-Ser-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H]1CCCN1 MKGIILKDUGDRRO-FXQIFTODSA-N 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- YQHZVYJAGWMHES-ZLUOBGJFSA-N Ser-Ala-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YQHZVYJAGWMHES-ZLUOBGJFSA-N 0.000 description 1
- OHKFXGKHSJKKAL-NRPADANISA-N Ser-Glu-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O OHKFXGKHSJKKAL-NRPADANISA-N 0.000 description 1
- YMTLKLXDFCSCNX-BYPYZUCNSA-N Ser-Gly-Gly Chemical compound OC[C@H](N)C(=O)NCC(=O)NCC(O)=O YMTLKLXDFCSCNX-BYPYZUCNSA-N 0.000 description 1
- ZOPISOXXPQNOCO-SVSWQMSJSA-N Ser-Ile-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](CO)N ZOPISOXXPQNOCO-SVSWQMSJSA-N 0.000 description 1
- AMRRYKHCILPAKD-FXQIFTODSA-N Ser-Met-Asn Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CO)N AMRRYKHCILPAKD-FXQIFTODSA-N 0.000 description 1
- FZEUTKVQGMVGHW-AVGNSLFASA-N Ser-Phe-Gln Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(N)=O)C(O)=O FZEUTKVQGMVGHW-AVGNSLFASA-N 0.000 description 1
- PYTKULIABVRXSC-BWBBJGPYSA-N Ser-Ser-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PYTKULIABVRXSC-BWBBJGPYSA-N 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 101000794214 Staphylococcus aureus Toxic shock syndrome toxin-1 Proteins 0.000 description 1
- GNHRVXYZKWSJTF-HJGDQZAQSA-N Thr-Asp-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N)O GNHRVXYZKWSJTF-HJGDQZAQSA-N 0.000 description 1
- RRRRCRYTLZVCEN-HJGDQZAQSA-N Thr-Leu-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O RRRRCRYTLZVCEN-HJGDQZAQSA-N 0.000 description 1
- IJVNLNRVDUTWDD-MEYUZBJRSA-N Thr-Leu-Tyr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O IJVNLNRVDUTWDD-MEYUZBJRSA-N 0.000 description 1
- ZSPQUTWLWGWTPS-HJGDQZAQSA-N Thr-Lys-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O ZSPQUTWLWGWTPS-HJGDQZAQSA-N 0.000 description 1
- NDZYTIMDOZMECO-SHGPDSBTSA-N Thr-Thr-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O NDZYTIMDOZMECO-SHGPDSBTSA-N 0.000 description 1
- KPMIQCXJDVKWKO-IFFSRLJSSA-N Thr-Val-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O KPMIQCXJDVKWKO-IFFSRLJSSA-N 0.000 description 1
- AKHDFZHUPGVFEJ-YEPSODPASA-N Thr-Val-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O AKHDFZHUPGVFEJ-YEPSODPASA-N 0.000 description 1
- GQHAIUPYZPTADF-FDARSICLSA-N Trp-Ile-Arg Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)=CNC2=C1 GQHAIUPYZPTADF-FDARSICLSA-N 0.000 description 1
- ILDJYIDXESUBOE-HSCHXYMDSA-N Trp-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N ILDJYIDXESUBOE-HSCHXYMDSA-N 0.000 description 1
- MEZCXKYMMQJRDE-PMVMPFDFSA-N Trp-Leu-Tyr Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)CC(C)C)C(O)=O)C1=CC=C(O)C=C1 MEZCXKYMMQJRDE-PMVMPFDFSA-N 0.000 description 1
- YTYHAYZPOARHAP-HOCLYGCPSA-N Trp-Lys-Gly Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)O)N YTYHAYZPOARHAP-HOCLYGCPSA-N 0.000 description 1
- WHJVRIBYQWHRQA-NQCBNZPSSA-N Trp-Phe-Ile Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CC=CC=C1 WHJVRIBYQWHRQA-NQCBNZPSSA-N 0.000 description 1
- SMLCYZYQFRTLCO-UWJYBYFXSA-N Tyr-Cys-Ala Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CS)C(=O)N[C@@H](C)C(O)=O SMLCYZYQFRTLCO-UWJYBYFXSA-N 0.000 description 1
- NGALWFGCOMHUSN-AVGNSLFASA-N Tyr-Gln-Asp Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O NGALWFGCOMHUSN-AVGNSLFASA-N 0.000 description 1
- PRONOHBTMLNXCZ-BZSNNMDCSA-N Tyr-Leu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 PRONOHBTMLNXCZ-BZSNNMDCSA-N 0.000 description 1
- WDGDKHLSDIOXQC-ACRUOGEOSA-N Tyr-Leu-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 WDGDKHLSDIOXQC-ACRUOGEOSA-N 0.000 description 1
- SOAUMCDLIUGXJJ-SRVKXCTJSA-N Tyr-Ser-Asn Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O SOAUMCDLIUGXJJ-SRVKXCTJSA-N 0.000 description 1
- IEWKKXZRJLTIOV-AVGNSLFASA-N Tyr-Ser-Gln Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O IEWKKXZRJLTIOV-AVGNSLFASA-N 0.000 description 1
- BXJQKVDPRMLGKN-PMVMPFDFSA-N Tyr-Trp-Leu Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 BXJQKVDPRMLGKN-PMVMPFDFSA-N 0.000 description 1
- QRCBQDPRKMYTMB-IHPCNDPISA-N Tyr-Trp-Ser Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC3=CC=C(C=C3)O)N QRCBQDPRKMYTMB-IHPCNDPISA-N 0.000 description 1
- UEOOXDLMQZBPFR-ZKWXMUAHSA-N Val-Ala-Asn Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](C(C)C)N UEOOXDLMQZBPFR-ZKWXMUAHSA-N 0.000 description 1
- ASQFIHTXXMFENG-XPUUQOCRSA-N Val-Ala-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O ASQFIHTXXMFENG-XPUUQOCRSA-N 0.000 description 1
- DNOOLPROHJWCSQ-RCWTZXSCSA-N Val-Arg-Thr Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O DNOOLPROHJWCSQ-RCWTZXSCSA-N 0.000 description 1
- CXWJFWAZIVWBOS-XQQFMLRXSA-N Val-Lys-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@@H]1C(=O)O)N CXWJFWAZIVWBOS-XQQFMLRXSA-N 0.000 description 1
- AIWLHFZYOUUJGB-UFYCRDLUSA-N Val-Phe-Tyr Chemical compound C([C@H](NC(=O)[C@@H](N)C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=CC=C1 AIWLHFZYOUUJGB-UFYCRDLUSA-N 0.000 description 1
- DEGUERSKQBRZMZ-FXQIFTODSA-N Val-Ser-Ala Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O DEGUERSKQBRZMZ-FXQIFTODSA-N 0.000 description 1
- JAIZPWVHPQRYOU-ZJDVBMNYSA-N Val-Thr-Thr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](C(C)C)N)O JAIZPWVHPQRYOU-ZJDVBMNYSA-N 0.000 description 1
- PFMSJVIPEZMKSC-DZKIICNBSA-N Val-Tyr-Glu Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N PFMSJVIPEZMKSC-DZKIICNBSA-N 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 108010041407 alanylaspartic acid Proteins 0.000 description 1
- 108010047495 alanylglycine Proteins 0.000 description 1
- 108010087924 alanylproline Proteins 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 108010062796 arginyllysine Proteins 0.000 description 1
- 108010069205 aspartyl-phenylalanine Proteins 0.000 description 1
- 108010047857 aspartylglycine Proteins 0.000 description 1
- 108010092854 aspartyllysine Proteins 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 108010009297 diglycyl-histidine Proteins 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 231100000507 endocrine disrupting Toxicity 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 230000002070 germicidal effect Effects 0.000 description 1
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 1
- 108010027668 glycyl-alanyl-valine Proteins 0.000 description 1
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 1
- 108010045126 glycyl-tyrosyl-glycine Proteins 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 108010036413 histidylglycine Proteins 0.000 description 1
- 108010092114 histidylphenylalanine Proteins 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 108010051673 leucyl-glycyl-phenylalanine Proteins 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 108010054155 lysyllysine Proteins 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 108010034507 methionyltryptophan Proteins 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 108010024654 phenylalanyl-prolyl-alanine Proteins 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003405 preventing effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108010053725 prolylvaline Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 108010061238 threonyl-glycine Proteins 0.000 description 1
- 108010045269 tryptophyltryptophan Proteins 0.000 description 1
- 108010051110 tyrosyl-lysine Proteins 0.000 description 1
- 108010020532 tyrosyl-proline Proteins 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N31/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic oxygen or sulfur compounds
- A01N31/08—Oxygen or sulfur directly attached to an aromatic ring system
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N33/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic nitrogen compounds
- A01N33/02—Amines; Quaternary ammonium compounds
- A01N33/08—Amines; Quaternary ammonium compounds containing oxygen or sulfur
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
- A23L29/035—Organic compounds containing oxygen as heteroatom
- A23L29/04—Fatty acids or derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
- A23L3/34—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals
- A23L3/3454—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals in the form of liquids or solids
- A23L3/3463—Organic compounds; Microorganisms; Enzymes
- A23L3/34635—Antibiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
- A23L3/34—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals
- A23L3/3454—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals in the form of liquids or solids
- A23L3/3463—Organic compounds; Microorganisms; Enzymes
- A23L3/3481—Organic compounds containing oxygen
- A23L3/3508—Organic compounds containing oxygen containing carboxyl groups
- A23L3/3517—Carboxylic acid esters
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/10—Preserving against microbes
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Agronomy & Crop Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Dentistry (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Description
본 발명은 포도상구균 박테리오파지 유래 신규 엔도라이신(endolysin) LysSA97과 오일성분을 함유하는 세균 사멸용 조성물에 관한 것으로, 구체적으로는 '박테리오파지 유래 신규 엔도라이신 LysSA97'과, '에센셜 오일(essential oil) 성분인 카바크롤(carvacrol), 신남알데하이드(cinnamaldehyde) 및 티몰(thymol) 중 선택되는 하나 이상'을 함유하는 세균 사멸용 조성물에 관한 것이다. The present invention relates to a novel endolysin LysSA97 derived from Staphylococcus aureus bacteriophage and a composition for killing bacteria containing an oil component. More specifically, the present invention relates to a novel endocrine lysine LysSA97 derived from bacteriophage and an essential oil component At least one selected from the group consisting of carvacrol, cinnamaldehyde and thymol.
황색포도상구균(Staphylococcus aureus)은 그람 양성균이며, 포자를 형성하지 않는 통성혐기성균으로 주로 가축 분변, 염증 상처부위 혹은 사람의 손이 많이 닿는 조리도구 등에서 발견된다. 이는 인간과 동물에 감염하여 수술 후 감염, 농양, 심장 내막염 및 독소 증후군 등의 심각한 질병을 유도하는 대표적인 병원성 세균이다. 또한, 포도상구균이 내는 TSST-1, EF, 알파(alpha), 베타(beta), 델타(delta) 독소 등으로 인해 심각한 식중독을 유발하기도 한다. 이러한 포도상구균을 제어하기 위해 현재까지는 항생제가 주로 사용되어 왔지만 이는 메티실린 저항성 포도상구균 균주(Methicillin-resistant S. aureus) 등의 세균을 발생시키는 문제를 유발했다. Staphylococcus aureus is a gram-positive bacterium that is a sporadic anaerobic bacterium that does not form spores. It is found mainly in livestock feces, inflammation scarred areas, or cooking utensils that have a lot of human hands. It is a typical pathogenic bacterium that infects humans and animals and induces serious diseases such as postoperative infection, abscess, endocarditis and toxin syndrome. In addition, TSST-1, EF, alpha, beta, and delta toxins from Staphylococcus aureus can cause severe food poisoning. To date, antibiotics have been used to control these staphylococci, but this has led to the problem of producing bacteria such as methicillin-resistant S. aureus.
이러한 문제를 해결하는 균의 사멸을 위해 최근 주목받고 있는 것이 엔도라이신(endolysin)이다. 엔도라이신은 박테리오파지(bacteriophage)가 세균 세포벽의 펩티도글리칸(peptidoglycan)을 분해하기 위해 만드는 효소로서 박테리오파지의 용균 생활사 마지막 단계에 비리온(virion)을 세포 밖으로 방출시킬 때 사용된다. 엔도라이신은 낮은 농도로 세균을 빠르게 사멸시키고, 저항성 균이 잘 형성되지 않는 특징을 가지므로 최근 항생제 대체 물질로 각광받고 있다. Endolysin has recently attracted attention for the killing of bacteria that solve these problems. Endorithine is an enzyme that bacteriophage is used to break down peptidoglycan in bacterial cell walls and is used to release virions out of the cell at the last stage of bacterial life cycle of bacteriophage. Endorylsin is rapidly emerging as a substitute for antibiotics because it rapidly kills bacteria at low concentrations and does not form resistant bacteria.
다만, 포도상구균 박테리오파지 유래 신규 엔도라이신 LysSA97은 단독 처리 시, 기존에 보고된 다른 엔도라이신들에 비해 과량을 처리해야 황색포도상구균의 사멸효과를 보이는 문제가 있다. However, the new endorhysin LysSA97 derived from Staphylococcus aureus bacteriophage has a problem of showing the killing effect of Staphylococcus aureus only when it is treated excessively in comparison with other endorhysines reported previously.
따라서, 신규 엔도라이신 LysSA97의 처리량을 감소시키면서도 포도상구균 사멸효과는 우수하게 증가시킬 수 있는 방법이 필요한 실정이다. Therefore, there is a need for a method capable of increasing the staphylococcus killing effect while reducing the throughput of the novel endorhysin LysSA97.
본 발명은 LysSA97 엔도라이신 단독 처리 시 과량을 처리해야 하는 문제를 해결하고자, LysSA97 엔도라이신과 오일 성분을 병용처리하여, 각각을 단독 사용하였을 경우보다 우수한 균 사멸능을 보이는 세균 사멸 조성물을 개발하여 제공하고자 한다.The present invention solves the problem of over-treatment of LysSA97 endorhysin alone, and has developed and produced a bacteriostatic composition that exhibits better bactericidal activity when LysSA97 endoryline and oil components are used in combination, I want to.
상기의 목적을 달성하기 위해 본 발명은 카바크롤(carvacrol), 신남알데하이드(cinnamaldehyde) 및 티몰(thymol) 중 선택되는 어느 하나 이상의 화합물과 서열번호 2의 아미노산 서열을 갖는 엔도라이신 LysSA97을 함유하는 세균 사멸용 조성물을 제공한다. In order to accomplish the above object, the present invention provides a method for producing a bacterium containing at least one compound selected from carvacrol, cinnamaldehyde and thymol and endocytosine LysSA97 having the amino acid sequence of SEQ ID NO: 2 ≪ / RTI >
본 발명에서는, 카바크롤(carvacrol), 신남알데하이드(cinnamaldehyde) 및 티몰(thymol) 중 선택되는 어느 하나 이상의 화합물과 서열번호 2의 아미노산 서열을 갖는 엔도라이신 LysSA97을 병용 처리하였을 경우, 두 물질의 시너지 효과로 인해, 이를 각각 처리하였을 때에 비해 현저히 높은 살균효과가 발생함을 확인하였다. 하기 본 발명의 실험에 의할 경우, 병용 처리시 단독 처리에 비해 약 10배 정도의 우수한 포도상구균의 살균가 있음을 확인하였다. In the present invention, when endocrine LysSA97 having the amino acid sequence of SEQ ID NO: 2 is used in combination with at least one compound selected from carvacrol, cinnamaldehyde and thymol, synergy effect of the two substances , It was confirmed that sterilization effect remarkably higher than that of each treatment was generated. According to the experiment of the present invention as described below, it was confirmed that sterilization of Staphylococcus aureus was about 10 times as high as that of single treatment in combination treatment.
본 발명의 세균 사멸용 조성물은, 본 발명의 카바크롤(carvacrol), 신남알데하이드(cinnamaldehyde) 및 티몰(thymol) 중 선택되는 어느 하나 이상의 화합물과 서열번호 2의 아미노산 서열을 갖는 엔도라이신 LysSA97을 구성성분으로 하여 조성되는데, 이들 성분 외에 당업계에서 사용되는 다양한 보조제 (안정제 등)를 포함할 수 있다. The composition for killing bacteria according to the present invention comprises at least one compound selected from the group consisting of carvacrol, cinnamaldehyde and thymol of the present invention and endocrystal LysSA97 having the amino acid sequence of SEQ ID NO: 2, . In addition to these components, various adjuvants (stabilizers, etc.) used in the art may be included.
본 발명의 세균 사멸용 조성물은, 세균 사멸 효능을 발휘하는 다양한 제제를 포함하는 개념인데, 항균제, 항생제 등의 용어를 포함하는 개념이다. 본 발명은 박테리오파지 유래의 엔도라이신과 정유 (essential oil) 성분의 일종인 카바크롤(carvacrol), 신남알데하이드(cinnamaldehyde) 또는 티몰(thymol)을 사용하기 때문에, 통상적인 합성 화합물 유래 항생제가 불러일으키는 내성의 문제로부터 어느 정도 자유로울 수 있는 장점이 있다. The composition for killing bacteria according to the present invention is a concept including a variety of agents exhibiting bactericidal killing efficacy, and is a concept including terms such as antibacterial agents and antibiotics. Since the present invention uses endolysin derived from bacteriophage and carvacrol, cinnamaldehyde or thymol, which is a kind of essential oil component, it is possible to prevent the resistance of antibiotics derived from conventional synthetic compounds There is an advantage of being free from the problem to some extent.
한편, 본 발명은 카바크롤(carvacrol), 신남알데하이드(cinnamaldehyde) 및 티몰(thymol) 중 선택되는 어느 하나 이상의 화합물과 서열번호 2의 아미노산 서열을 갖는 신규 엔도라이신 LysSA97을 함유하는 식품 첨가제를 제공한다. On the other hand, the present invention provides a food additive comprising at least one compound selected from carvacrol, cinnamaldehyde and thymol and a novel endorhysinase LysSA97 having the amino acid sequence of SEQ ID NO: 2.
또한, 본 발명은 카바크롤(carvacrol), 신남알데하이드(cinnamaldehyde) 및 티몰(thymol) 중 선택되는 어느 하나 이상의 화합물과 서열번호 2의 아미노산 서열을 갖는 신규 엔도라이신 LysSA97을 함유하는 식품을 제공한다. In addition, the present invention provides a food containing a novel endorhysinase LysSA97 having the amino acid sequence of SEQ ID NO: 2 and at least one compound selected from carvacrol, cinnamaldehyde and thymol.
본 발명의 식품 첨가제 또는 식품에 있어서, 상기 식품은 병원성 균에 오염되기 쉬운 것이라면, 어느 것에도 적용될 수 있는데, 일 예로는 스타필로코커스 아우레우스(Staphylococcus aureus)에 오염되기 쉬운 것일 수 있다. 오염되기 쉬운 식품의 예로는 우유, 고기 등이 있다. In the food additive or food of the present invention, the food can be applied to any food which is susceptible to pathogenic fungi. For example, the food may be susceptible to Staphylococcus aureus . Examples of foods that are susceptible to contamination include milk and meat.
본 발명의 식품 첨가제에는 본 발명의 카바크롤(carvacrol), 신남알데하이드(cinnamaldehyde) 및 티몰(thymol) 중 선택되는 어느 하나 이상의 화합물과 서열번호 2의 아미노산 서열을 갖는 신규 엔도라이신 LysSA97외에 당업계에서 사용되는 다양한 보조제 (예로서, 안정제 등)를 포함할 수 있다. The food additive of the present invention may contain at least one compound selected from the group consisting of carvacrol, cinnamaldehyde and thymol of the present invention and a novel endorhysinase LysSA97 having the amino acid sequence of SEQ ID NO: (E. G., Stabilizers, etc.).
본 발명은 LysSA97 엔도라이신과 에센셜 오일(essential oil)을 병용처리함으로써, 이를 각각 처리하였을 때의 살균효과보다 현저히 우수한 살균효과를 발휘한다. 본 발명의 실험에 의할 경우, 엔도라이신과 에센셜 오일을 각각 처리한 경우보다 약 10배 정도의 우수한 시너지 효과(synergy effect)를 발휘한다. The present invention exerts a sterilizing effect remarkably superior to the disinfecting effect when treated with LysSA97 endoryline and essential oil in combination. According to the experiment of the present invention, an excellent synergy effect of about 10 times as compared with the treatment with endorhysin and essential oil is exerted.
도 1의 'A'는 스타필로코커스 아우레우스(Staphylococcus aureus)에 LysSA97 엔도라이신(endolysin)과 카바크롤(carvacrol)을 각각 단독 또는 병용 처리하였을 때의 흡광도를 나타낸 그래프이고, 도 1의 'B'는 스타필로코커스 아우레우스(Staphylococcus aureus)에 LysSA97 엔도라이신과 신남알데하이드(cinnamaldehyde)를 각각 단독 또는 병용 처리하였을 때의 흡광도를 나타낸 그래프이며, 도 1의 'C'는 스타필로코커스 아우레우스(Staphylococcus aureus)에 LysSA97 엔도라이신과 티몰(thymol)을 각각 단독 또는 병용 처리하였을 때의 흡광도를 나타낸 그래프이다.
도 2의 'A'는 스타필로코커스 아우레우스에 LysSA97 엔도라이신과 카바크롤을 병용처리 또는 고농도 단독처리하였을 때의 흡광도를 나타낸 그래프이고, 도 2의 'B' 스타필로코커스 아우레우스에 LysSA97 엔도라이신과 카바크롤을 병용처리 또는 고농도 단독처리하였을 때의 생균수를 나타낸 그래프이다.
도 3은 10가지 종류의 스타필로코커스 아우레우스에 대해 LysSA97 엔도라이신과 카바크롤을 병용 또는 단독 처리하였을 때의 흡광도를 나타낸 그래프이다.
도 4는 LysSA97 엔도라이신과 카바크롤을 단독 또는 병용처리시, 세균 표면을 주사전자현미경으로 관찰한 결과이다.
도 5는 스타필로코커스 아우레우스로 인해 식중독 발생이 빈번한 식품에 LysSA97 엔도라이신과 카바크롤을 단독 또는 병용처리 후, 상온에서 사멸효과를 확인한 결과이다. 도 5의 'A'는 우유에 LysSA97 엔도라이신과 카바크롤을 단독 또는 병용처리 후, 상온에서 사멸효과를 확인한 결과이고, 도 5의 'B'는 소고기에 LysSA97 엔도라이신과 카바크롤을 단독 또는 병용처리 후, 상온에서 사멸효과를 확인한 결과이다.A 'in FIG. 1 is a graph showing the absorbance of LysSA97 endolysin and carvacrol in Staphylococcus aureus alone or in combination, and' B 'in FIG. 1 'Is a graph showing the absorbance when Staphylococcus aureus is treated with LysSA97 endoryline and cinnamaldehyde alone or in combination, and' C 'in FIG. 1 is a graph showing the absorbance of Staphylococcus aureus ( Staphylococcus aureus ), LysSA97 endorhysin and thymol, respectively, alone or in combination.
2 is a graph showing the absorbance of LysSA97 endorhysin and carbacol in combination with Staphylococcus aureus at the time of concurrent treatment or treatment with high concentration of LysSA97 and endotriazine LysSA97 in the 'B' staphylococcus aureus of FIG. 2 Fig. 2 is a graph showing the number of viable cells when endorhysin and carbacol were co-treated or treated at a high concentration alone. Fig.
Fig. 3 is a graph showing the absorbance of 10 types of Staphylococcus aureus when LysSA97 endoryline and carbacol were used in combination or alone. Fig.
Fig. 4 shows the result of observing the surface of bacteria with a scanning electron microscope when LysSA97 endorhynes and carbacol were used alone or in combination. Fig.
FIG. 5 shows the result of confirming the killing effect at room temperature after treating LysSA97 endorhynes and carbacol alone or in combination with foods frequently caused by food poisoning caused by Staphylococcus aureus. 5 shows the result of confirming the killing effect at room temperature after treating LysSA97 endorhynes and carbacol alone or in combination with milk in milk. In FIG. 5, 'B' indicates that the beef contains LysSA97 endorhynes and carbacol alone or in combination After treatment, it was the result of confirming the killing effect at room temperature.
이하, 본 발명의 내용을 하기 실시예를 통해 더욱 상세히 설명하고자 한다. 다만, 본 발명의 권리범위가 하기 실시예에만 한정되는 것은 아니고, 그와 등가의 기술적 사상의 변형까지를 포함한다.Hereinafter, the present invention will be described in more detail with reference to the following examples. However, the scope of the present invention is not limited to the following embodiments, and includes modifications of equivalent technical ideas.
[[ 실시예Example 1 내지 3: 1 to 3: LysSA97LysSA97 엔도라이신과Endorhysin and 에센셜Essential 오일 성분의 혼합물 제조] Preparation of a mixture of oil components]
pET28a-lysSA97 재조합 플라스미드로 형질전환된 대장균을 LB 액체 배지에 접종한 후, 600 nm 파장에서의 흡광도가 1.0이 될 때, 최종 농도가 1 mM이 되도록 IPTG (Isopropyl β-D-1-thiohalactopytanoside)를 첨가하여 재조합 엔도라이신의 발현을 유도하였다. When E. coli transformed with pET28a-lysSA97 recombinant plasmid was inoculated into LB liquid medium, IPTG (Isopropyl β-D-1-thiohalactopytanoside) was added so that the final concentration was 1 mM when absorbance at a wavelength of 600 nm was 1.0 To induce the expression of recombinant endorhysin.
18℃에서 22시간 동안 더 배양한 후 원심분리하고, 세포 침전물을 파쇄하여 원심분리를 한 후, 상등액에 Ni-NTA 레진을 사용함으로써, LysSA97 엔도라이신 (서열번호 2의 아미노산 서열을 가지며, 이는 서열번호 1의 핵산서열로 암호화됨)을 순수분리하였다.The cells were further cultured at 18 DEG C for 22 hours, centrifuged, and the cell precipitates were disrupted and centrifuged. Then, Ni-NTA resin was used as a supernatant to obtain LysSA97 endorylate (having the amino acid sequence of SEQ ID NO: 2, 1 < / RTI > nucleic acid sequence) was purely isolated.
그 후, 포도상구균 균주인 스타필로코커스 아우레우스(Staphylococcus aureus) RN4220가 접종된 배지에, 최종 농도가 376 nM이 되도록 LysSA97 엔도라이신과, 최종농도 0.05%(w/v)이 되도록 카바크롤(carvacrol), 신남알데하이드(cinnamaldehyde) 및 티몰(thymol)을 각각 첨가하여, '376 nM LysSA97 엔도라이신+0.05%(w/v) 카바크롤 혼합물', '376 nM LysSA97 엔도라이신+0.05%(w/v) 신남알데하이드 혼합물' 및 '376 nM LysSA97 엔도라이신+0.05%(w/v) 티몰 혼합물' 을 제조하였다. Thereafter, LysSA97 endoryline was added to the medium inoculated with Staphylococcus aureus RN4220, a staphylococcal strain, to a final concentration of 376 nM, and a solution of carbachol ( 376 nM LysSA97 endorhysin + 0.05% (w / v) carbachol mixture, 376 nM LysSA97 endoryline + 0.05% (w / v) carvacrol, cinnamaldehyde and thymol, ) Shinnam aldehyde mixture " and " 376 nM LysSA97 endorhysin + 0.05% (w / v) thymol mixture ".
이때, '376 nM LysSA97 엔도라이신+0.05%(w/v) 카바크롤 혼합물'을 실시예 1, '376 nM LysSA97 엔도라이신+0.05%(w/v) 신남알데하이드 혼합물'을 실시예 2, '376 nM LysSA97 엔도라이신+0.05%(w/v) 티몰 혼합물'을 실시예 3으로 명명하여 하기 실험예에서 사용하였다. Example 2 376 nM LysSA97 endorhysin + 0.05% (w / v) cinnamaldehyde mixture was added to 376 nM LysSA97 endorhysin + 0.05% (w / v) nM LysSA97 endoryline + 0.05% (w / v) thymol mixture 'was named as Example 3 and used in the following experimental examples.
[[ 실험예Experimental Example 1: One: LysSA97LysSA97 엔도라이신과Endorhysin and 에센셜Essential 오일 성분의 혼합물에 의한 용균 효과 확인] Confirmation of lytic effect by mixture of oil components]
본 실험예에서는 상기 실시예 1 내지 3과, 각각의 단독 물질 처리군(LysSA97 엔도라이신 처리군, 카바크롤 처리군, 신남알데하이드 처리군, 티몰 처리군)의 용균 효과를 확인하고자 하였다. In this Experimental Example, the lytic effect of the above Examples 1 to 3 and the respective single substance treatment groups (LysSA97 endorlice treatment group, carbacol treatment group, cinnamaldehyde treatment group, and thymol treatment group) were examined.
이를 위해, 포도상구균 균주인 스타필로코커스 아우레우스(Staphylococcus aureus) RN4220가 접종된 배지에, '최종 농도가 376 nM이 되도록 LysSA97 엔도라이신을 첨가한 처리군', '최종농도 0.05%(w/v)이 되도록 카바크롤(carvacrol)을 첨가한 처리군', '최종농도 0.05%(w/v)이 되도록 신남알데하이드(cinnamaldehyde)를 첨가한 처리군' 및 '최종농도 0.05%(w/v)이 되도록 티몰(thymol)을 첨가한 처리군'을 단독 물질 처리군으로 제조하고, 실시예 1 내지 3이 이들 단독 물질 처리군에 비해 흡광도가 얼마나 감소하는지 (즉, 용균효과가 얼마나 높은지) 측정하였다. To this end, the medium inoculated with Staphylococcus aureus RN4220, a staphylococcal strain, was treated with LysSA97 end lysine to a final concentration of 376 nM, a final concentration of 0.05% (w / treated group to which cinnamaldehyde was added to a final concentration of 0.05% (w / v) and a final concentration of 0.05% (w / v) Treated group to which thymol was added to prepare a single substance treatment group and to measure how much the absorbance (i.e., the lytic effect) of Examples 1 to 3 was lower than those of the single substance treatment group .
실험결과, '376 nM LysSA97 엔도라이신+0.05%(w/v) 카바크롤 혼합물(실시예 1)', '376 nM LysSA97 엔도라이신+0.05%(w/v) 신남알데하이드 혼합물(실시예 2)' 및 '376 nM LysSA97 엔도라이신+0.05%(w/v) 티몰 혼합물(실시예 3)' 처리군의 흡광도는 각 물질을 단독으로 첨가한 처리군보다 현저히 낮은 흡광도를 보이는 것으로 나타났다 (도 1). (Example 2) '376 nM LysSA97 endorhysin + 0.05% (w / v) carbachol mixture (Example 1)', 376 nM LysSA97 endorhysin + 0.05% And the 376 nM LysSA97 endorhysin + 0.05% (w / v) thymol mixture (Example 3) 'treated group showed significantly lower absorbance than the group treated with each substance alone (FIG. 1).
도 1의 'A'는 스타필로코커스 아우레우스(Staphylococcus aureus)에 LysSA97 엔도라이신(endolysin)과 카바크롤(carvacrol)을 각각 단독 또는 병용 처리하였을 때의 흡광도를 나타낸 그래프이고, 도 1의 'B'는 스타필로코커스 아우레우스(Staphylococcus aureus)에 LysSA97 엔도라이신과 신남알데하이드(cinnamaldehyde)를 각각 단독 또는 병용 처리하였을 때의 흡광도를 나타낸 그래프이며, 도 1의 'C'는 스타필로코커스 아우레우스(Staphylococcus aureus)에 LysSA97 엔도라이신과 티몰(thymol)을 각각 단독 또는 병용처리 하였을 때의 흡광도를 나타낸 그래프이다.A 'in FIG. 1 is a graph showing the absorbance of LysSA97 endolysin and carvacrol in Staphylococcus aureus alone or in combination, and' B 'in FIG. 1 'Is a graph showing the absorbance when Staphylococcus aureus is treated with LysSA97 endoryline and cinnamaldehyde alone or in combination, and' C 'in FIG. 1 is a graph showing the absorbance of Staphylococcus aureus ( Staphylococcus aureus ), LysSA97 endorhysin and thymol, respectively, alone or in combination.
이상의 실험을 통해, LysSA97 엔도라이신과 에센셜 오일(essential oil) 성분을 병용 처리함으로써, 이를 각각 처리하였을 때보다 현저히 우수한 살균효과를 발휘하는 것으로 확인할 수 있었다. Through the above experiments, it was confirmed that LysSA97 endoryline and essential oil components were treated in combination to exert a remarkably excellent sterilizing effect compared with the treatment with each of them.
[[ 실험예Experimental Example 2: 2: LysSA97LysSA97 엔도라이신과Endorhysin and 카바크롤Carbacol (( carvacrolcarvacrol ) 혼합물의 용균(살균) 효과 측정]) Measuring the lytic (sterilization) effect of the mixture]
본 실험에서는 LysSA97 엔도라이신과 에센셜 오일 성분인 카바크롤, 신남알데하이드, 티몰의 처리농도를 높여 엔도라이신과 에센셜 오일 성분의 병용처리가 얼마만큼의 증진된 용균(살균) 효과를 나타내는지 확인해보고자 하였다. In this experiment, we tried to ascertain the effect of LysSA97 endorylase and essential oil components carbacol, cinnamaldehyde, and thymol on the treatment of endocrine disruption by combination treatment of endorhysin and essential oil.
본 실험예에서는 일 예로, 상기 실시예 1의 '376 nM LysSA97 엔도라이신+0.05%(w/v) 카바크롤 혼합물' 처리군과, LysSA97 엔도라이신과 카바크롤 각각 물질에 대해 상기 처리농도의 10배에 해당하는 농도로 단독 처리한 처리군의 용균 효과를 비교하고자 하였다. 즉, '376 nM LysSA97 엔도라이신+0.05%(w/v) 카바크롤 혼합물' 처리군, '3.76 μM LysSA97 엔도라이신' 처리군, '0.5%(w/v) 카바크롤' 처리군을 설정하고, 이들 처리군이 대조군에 비해 흡광도가 얼마나 감소하는지 측정하였다. In this experiment, for example, the treatment group of 376 nM LysSA97 endorhysin + 0.05% (w / v) carbachol mixture of Example 1 and the group treated with LysSA97 endorhysin and
또한, 포도상구균 균주에 LysSA97 엔도라이신과 카바크롤 각각 및 이들의 혼합물을 넣었을 때, 대조군에 비해 '생균수'가 얼마나 감소하는지도 측정하였다. In addition, when the staphylococcal strain was loaded with each of LysSA97 endorhysin and carbachol and a mixture thereof, the number of viable cells was decreased compared to the control.
실험결과, '376 nM LysSA97 엔도라이신+0.05%(w/v) 카바크롤 혼합물' 처리군의 흡광도는 상기 실험예 1과 동일하게 각 물질을 단독으로 첨가한 처리군보다 현저히 낮은 흡광도를 보였다. 이때, '376 nM LysSA97 엔도라이신+0.05%(w/v) 카바크롤 혼합물' 처리군의 흡광도는 각각 물질을 병용처리군 최종농도의 10배에 해당하는 농도로 처리한 것과 유사한 결과를 보였다 (도 2). As a result of the experiment, the absorbance of the '376 nM LysSA97 endorhysin + 0.05% (w / v) carbachol mixture' treatment group was significantly lower than that of the group treated with each substance alone as in Experimental Example 1. At this time, the absorbance of the '376 nM LysSA97 endorhysin + 0.05% (w / v) carbacol mixture' treatment group was similar to that of the material treated with 10 times the final concentration of the combined treatment group 2).
한편, 생균수의 경우에 있어서도, '376 nM LysSA97 엔도라이신+0.05%(w/v) 카바크롤 혼합물' 처리군이 각각 물질을 단독으로 첨가한 처리군보다 현저히 낮은 생균수를 보였다. 또한, '376 nM LysSA97 엔도라이신+0.05%(w/v) 카바크롤 혼합물' 처리군의 생균수는 엔도라이신 최종농도의 10배에 해당하는 '3.76 μM LysSA97 엔도라이신' 처리군과 유사한 결과를 보였다 (도 2). On the other hand, in the case of viable cell count, the number of viable cells was significantly lower in the group treated with 376 nM LysSA97 endorhysin + 0.05% (w / v) carbacol mixture than in the group treated alone with the substance alone. In addition, the number of viable cells in the '376 nM LysSA97 endorhysin + 0.05% (w / v) carbacol mixture' treatment group was similar to that of the 3.76 μM LysSA97 endorylase treatment group, which was 10 times the endolysin final concentration (Fig. 2).
도 2의 'A'는 스타필로코커스 아우레우스에 LysSA97 엔도라이신과 에센셜 오일 성분 중 카바크롤을 병용처리 또는 고농도 단독처리하였을 때의 흡광도를 나타낸 그래프이고, 도 2의 'B'는 스타필로코커스 아우레우스에 LysSA97 엔도라이신과 에센셜 오일 성분 중 카바크롤을 병용처리 또는 고농도 단독처리하였을 때의 생균수를 나타낸 그래프이다. 2 is a graph showing the absorbance of Staphylococcus aureus in combination with LysSA97 endorhynes and carbacol among essential oil components or in high concentrations alone, and 'B' in FIG. 2 is a graph showing the absorbance of Staphylococcus aureus LysSA97 is a graph showing the number of viable cells when LysSA97 endorylase is treated with a combination of carbacol and high concentration of essential oil components in aureus.
[[ 실험예Experimental Example 3: 3: LysSA97LysSA97 엔도라이신과Endorhysin and 카바크롤Carbacol (( carvacrolcarvacrol ) 혼합물의 다양한 ) A variety of mixtures 스타필Starfil 로코커스 아우레우스 균주에 대한 용균 효과 측정]Measurement of the lytic effect on the strain of Rocococcus aureus]
본 실험예에서는 상기 실험에서 사용한 스타필로코커스 아우레우스(Staphylococcus aureus) RN4220 균주 외에 다양한 스타필로코커스 아우레우스 균주를 사용하여 본 발명의 LysSA97 엔도라이신과 카바크롤 혼합물의 용균 효과를 측정하고자 하였다. In this experiment, the lytic effect of LysSA97 endorhynes and carbachol mixtures of the present invention was measured using various Staphylococcus aureus strains in addition to Staphylococcus aureus RN4220 strain used in the above experiment.
실험을 위하여, 스타필로코커스 아우레우스 CCARM 3089, 스타필로코커스 아우레우스 CCARM 3090, 스타필로코커스 아우레우스 ATCC 6538, 스타필로코커스 아우레우스 ATCC 23235, 스타필로코커스 아우레우스 ATCC 29213, 스타필로코커스 아우레우스 ATCC 25923, 스타필로코커스 아우레우스 ATCC 33586, 스타필로코커스 아우레우스 ATCC 33593, 스타필로코커스 아우레우스 KCTC 1916, 스타필로코커스 아우레우스 Newman 각각에 '376 nM LysSA97 엔도라이신+0.05%(w/v) 카바크롤 혼합물'을 처리하고, 흡광도를 측정하였다. For the experiment, Staphylococcus aureus CCARM 3089, Staphylococcus aureus CCARM 3090, Staphylococcus aureus ATCC 6538, Staphylococcus aureus ATCC 23235, Staphylococcus aureus ATCC 29213,
실험 결과, 모든 스타필로코커스 아우레우스 균주에 대해, '376 nM LysSA97 엔도라이신+0.05%(w/v) 카바크롤 혼합물' 처리군의 흡광도가 각 물질을 단독으로 첨가한 처리군보다 현저히 낮게 나타났다 (도 3). 도 3은 10가지 종류의 스타필로코커스 아우레우스에 대해 LysSA97 엔도라이신과 카바크롤을 병용 또는 단독 처리하였을 때의 흡광도를 나타낸 그래프이다.As a result, the absorbance of each Staphylococcus aureus strain treated with '376 nM LysSA97 endorhysin + 0.05% (w / v) carbacol mixture' was significantly lower than that of each substance added alone (Fig. 3). Fig. 3 is a graph showing the absorbance of 10 types of Staphylococcus aureus when LysSA97 endoryline and carbacol were used in combination or alone. Fig.
본 실험을 통해, LysSA97 엔도라이신과 에센스 오일 성분의 병용처리는 특정의 스타필로코커스 아우레우스 균주가 아닌 모든 스타필로코커스 아우레우스 균주에 대해 현저히 높은 살균효과가 나타나는 것으로 확인할 수 있었다. Through this experiment, it was confirmed that the combined treatment of LysSA97 endoryline and the essence oil component showed a remarkably high sterilization effect on all Staphylococcus aureus strains that are not specific Staphylococcus aureus strains.
[[ 실험예Experimental Example 4: 주사전자현미경을 통한 포도상구균( 4: Staphylococcus through scanning electron microscope ( 스타필로코커스Staphylococcus 아우레우스Aureus )의)of 생균수의Viable cell count 감소 관찰] Decrease observation]
본 실험예에서는 포도상구균(스타필로코커스 아우레우스) 균주에 LysSA97 엔도라이신과 카바크롤을 각각 또는 병용하여 처리하였을 때, 대조군에 비해 균 표면이 어떻게 변하는지 주사전자현미경으로 관찰하였다. In this experimental example, when the LysSA97 endorylase and carbacol were treated with Staphylococcus aureus (Staphylococcus aureus), respectively, the surface of the bacteria was changed by the scanning electron microscope compared to the control.
관찰결과, '376 nM LysSA97 엔도라이신+0.05%(w/v) 카바크롤 혼합물' 처리군의 표면이 각 물질을 단독으로 첨가한 처리군보다 더 많은 용균을 보였음을 확인할 수 있었다 (도 4). 도 4는 LysSA97 엔도라이신과 카바크롤을 단독 또는 병용처리 시 세균 표면을 주사전자현미경으로 관찰한 결과이다. As a result, it was confirmed that the surface of the '376 nM LysSA97 endorhysin + 0.05% (w / v) carbacol mixture' treated group showed more lysis than the group treated with each substance alone (FIG. 4). Fig. 4 shows the result of observing the surface of bacteria on a scanning electron microscope when LysSA97 endorylase and carbacol were used alone or in combination.
[[ 실험예Experimental Example 5: 실제 식품 내에서 5: In real food LysSA97LysSA97 엔도라이신과Endorhysin and 카바크롤Carbacol 혼합물의 생균 사멸 효과 확인] Determination of viable cell killing effect of mixture]
본 실험예에서는 포도상구균(스타필로코커스 아우레우스)에 의한 식중독이 빈번하게 일어나는 것으로 보고된 우유(유제품)와 소고기(육제품)에 LysSA97 엔도라이신 및 카바크롤 혼합물을 처리하여, 그 살균 효과를 확인하고자 하였다. In this experiment, milk (milk products) and beef (meat products), which are reported to be frequently infected by Staphylococcus aureus (Staphylococcus aureus), are treated with LysSA97 endorhysin and carbachol mixture, Respectively.
이를 위해, 스타필로코커스 아우레우스가 약 105 CFU/ml 수준으로 오염되어 있던 우유(유제품)와 소고기(육제품)에 대해, 1.88 μM LysSA97 엔도라이신 처리군, 0.1%(w/v) 카바크롤 처리군 및 '1.88 μM LysSA97 엔도라이신과 0.1%(w/v) 카바크롤 혼합물 처리군'을 각각 처리하고, 실온에 보관하며 살균효과를 확인하였다. For this purpose, milk (dairy products) and beef (meat products) contaminated with Staphylococcus aureus at a level of about 10 5 CFU / ml were treated with 1.88 μM LysSA97 endorylase treatment group, 0.1% (w / v) Treated with croche and 0.1% (w / v) carbacol mixture treated with 1.88 [mu] M LysSA97 endorhysin and stored at room temperature to confirm the sterilization effect.
실험결과, 두 식품에서 모두 병용 처리한 처리군이 단독 처리한 처리군에 비해 생균수가 현저히 감소함을 확인할 수 있었다. 도 5는 스타필로코커스 아우레우스로 인해 식중독 발생이 빈번한 식품에 LysSA97 엔도라이신과 카바크롤을 단독 또는 병용처리 후, 상온에서 사멸효과를 확인한 결과이다. 도 5의 'A'는 우유에 LysSA97 엔도라이신과 카바크롤을 단독 또는 병용처리 후, 상온에서 사멸효과를 확인한 결과이고, 도 5의 'B'는 소고기에 LysSA97 엔도라이신과 카바크롤을 단독 또는 병용처리 후, 상온에서 사멸효과를 확인한 결과이다.As a result, it was confirmed that the number of viable cells was significantly reduced in the two groups of food, compared with the group treated alone. FIG. 5 shows the result of confirming the killing effect at room temperature after treating LysSA97 endorhynes and carbacol alone or in combination with foods frequently caused by food poisoning caused by Staphylococcus aureus. 5 shows the result of confirming the killing effect at room temperature after treating LysSA97 endorhynes and carbacol alone or in combination with milk in milk. In FIG. 5, 'B' indicates that the beef contains LysSA97 endorhynes and carbacol alone or in combination After treatment, it was the result of confirming the killing effect at room temperature.
상기와 같은 결과는, LysSA97 엔도라이신과 카바크롤의 병용 처리 시, 각각의 물질을 단독으로 처리하였을 때에 비해, 각 효과의 합보다 더욱 강한 시너지 살균 효과가, 식품 내에서도 효과적으로 일어난다는 사실을 보여주며, 이를 통해 향후 엔도라이신과 에센셜 오일의 혼합물이 신규의 식품 첨가 살균제로 사용될 수 있음을 의미하는 것이다. The above results show that the synergistic germicidal effect stronger than the sum of the respective effects is effectively achieved in the food, as compared with the case where the respective substances are treated alone, when LysSA97 endoryline and carbacol are used in combination, This means that a mixture of endorhysin and essential oil can be used as a new food-additive disinfectant in the future.
<110> Seoul National University R&DB Foundation <120> Antibiotic composition with novel endolysin LysSA97 from Staphylococcus aureus bacteriophage and compound from essential oil <130> YP-16-157 <160> 2 <170> KoPatentIn 3.0 <210> 1 <211> 1413 <212> DNA <213> Staphylococcus aureus <400> 1 atgccgtcgg ttaggacata cagtcaagct attagttatc ttaaaagttt agagggtaag 60 gcgtggaatc cagacaatgc atttggatgt caatgcttcg atactgctaa ccaatattgg 120 ctttacttat ttaatcacag gttgaaaggt gtgggcgctg cagacattcc aacatggaat 180 gatttcacta acgaggcaac cgtttacgaa aatactgtgt cgtttcaagc attgcctggc 240 gatgtcgtta tttttaaccg taattatggt ggtggttatg gtcatgtagg tattgtaata 300 agcgctacgt tagattctat aactatttta gagcagaact ggctaggcgg tgcttactgg 360 agtccaccag aagttactac aagacgcaca cacggctacg acttccctat gtggtttatc 420 cgtccattct acgcaaaaga aacgaccgct aataagctaa gaagcgcagt gaagccagtt 480 aaacaagata agttatcaaa aggtaaaaaa atcatgcttg tggctggtca tggtattggt 540 gcatactcta acgacccagg tgccgttgcg aatggagaaa acgaaagaga ttttaaccgt 600 aaaaatatta tacctagagt gaaaaagtat cttgagtcag taggcaacac agtattgtta 660 tacggtggca actcgatgaa tcaagattta tatcaagata cattgtacgg tcaacgtgtt 720 ggaaactata aagattatgg catgtactgg attaaaagtg aagtcaaacc ggatgcaatc 780 atagagtttc atttagattc tgctagccca caagcaagtg gcgggcatgt aatcattagc 840 gatcgtttcc cagctgatga cattgacaag gcattaagta gtgcattaga taaaacagtg 900 ggtaaaataa gaggtgtgac acctagaggg gatttattga acgctaacgt gtctgctgat 960 cttaatctta attatcgttt aatcgaatta ggttttatca catctacgaa agatttaaac 1020 tacattaaaa acaatttaga cagcttcacg aagcggattg ctgaagccat taacggcaga 1080 caaattgatg cgccaagtag taagccaagc gctgacaaaa taacatggaa ttggaaaggc 1140 gtattttatc ctaatccaga aaaagctata agagtcagaa aaacagctgg attaaccggc 1200 acagtcgttg aagaagattc atggctatac acaaaagatg attgggtaaa attcgaccaa 1260 gtcattaaaa aagatggcta ctggtggatt agattcaaat atcaacgtga gggctctagt 1320 actaacaatt tctattgtgc agtgtgtaga attactgata aggaacaaaa gattaaaaat 1380 gaaaaatatt ggggcacgat tgagtgggct taa 1413 <210> 2 <211> 470 <212> PRT <213> Staphylococcus aureus <400> 2 Met Pro Ser Val Arg Thr Tyr Ser Gln Ala Ile Ser Tyr Leu Lys Ser 1 5 10 15 Leu Glu Gly Lys Ala Trp Asn Pro Asp Asn Ala Phe Gly Cys Gln Cys 20 25 30 Phe Asp Thr Ala Asn Gln Tyr Trp Leu Tyr Leu Phe Asn His Arg Leu 35 40 45 Lys Gly Val Gly Ala Ala Asp Ile Pro Thr Trp Asn Asp Phe Thr Asn 50 55 60 Glu Ala Thr Val Tyr Glu Asn Thr Val Ser Phe Gln Ala Leu Pro Gly 65 70 75 80 Asp Val Val Ile Phe Asn Arg Asn Tyr Gly Gly Gly Tyr Gly His Val 85 90 95 Gly Ile Val Ile Ser Ala Thr Leu Asp Ser Ile Thr Ile Leu Glu Gln 100 105 110 Asn Trp Leu Gly Gly Ala Tyr Trp Ser Pro Pro Glu Val Thr Thr Arg 115 120 125 Arg Thr His Gly Tyr Asp Phe Pro Met Trp Phe Ile Arg Pro Phe Tyr 130 135 140 Ala Lys Glu Thr Thr Ala Asn Lys Leu Arg Ser Ala Val Lys Pro Val 145 150 155 160 Lys Gln Asp Lys Leu Ser Lys Gly Lys Lys Ile Met Leu Val Ala Gly 165 170 175 His Gly Ile Gly Ala Tyr Ser Asn Asp Pro Gly Ala Val Ala Asn Gly 180 185 190 Glu Asn Glu Arg Asp Phe Asn Arg Lys Asn Ile Ile Pro Arg Val Lys 195 200 205 Lys Tyr Leu Glu Ser Val Gly Asn Thr Val Leu Leu Tyr Gly Gly Asn 210 215 220 Ser Met Asn Gln Asp Leu Tyr Gln Asp Thr Leu Tyr Gly Gln Arg Val 225 230 235 240 Gly Asn Tyr Lys Asp Tyr Gly Met Tyr Trp Ile Lys Ser Glu Val Lys 245 250 255 Pro Asp Ala Ile Ile Glu Phe His Leu Asp Ser Ala Ser Pro Gln Ala 260 265 270 Ser Gly Gly His Val Ile Ile Ser Asp Arg Phe Pro Ala Asp Asp Ile 275 280 285 Asp Lys Ala Leu Ser Ser Ala Leu Asp Lys Thr Val Gly Lys Ile Arg 290 295 300 Gly Val Thr Pro Arg Gly Asp Leu Leu Asn Ala Asn Val Ser Ala Asp 305 310 315 320 Leu Asn Leu Asn Tyr Arg Leu Ile Glu Leu Gly Phe Ile Thr Ser Thr 325 330 335 Lys Asp Leu Asn Tyr Ile Lys Asn Asn Leu Asp Ser Phe Thr Lys Arg 340 345 350 Ile Ala Glu Ala Ile Asn Gly Arg Gln Ile Asp Ala Pro Ser Ser Lys 355 360 365 Pro Ser Ala Asp Lys Ile Thr Trp Asn Trp Lys Gly Val Phe Tyr Pro 370 375 380 Asn Pro Glu Lys Ala Ile Arg Val Arg Lys Thr Ala Gly Leu Thr Gly 385 390 395 400 Thr Val Val Glu Glu Asp Ser Trp Leu Tyr Thr Lys Asp Asp Trp Val 405 410 415 Lys Phe Asp Gln Val Ile Lys Lys Asp Gly Tyr Trp Trp Ile Arg Phe 420 425 430 Lys Tyr Gln Arg Glu Gly Ser Ser Thr Asn Asn Phe Tyr Cys Ala Val 435 440 445 Cys Arg Ile Thr Asp Lys Glu Gln Lys Ile Lys Asn Glu Lys Tyr Trp 450 455 460 Gly Thr Ile Glu Trp Ala 465 470 <110> Seoul National University R & DB Foundation <120> Antibiotic composition with novel endolysin LysSA97 from Staphylococcus aureus bacteriophage and compound from essential oil <130> YP-16-157 <160> 2 <170> KoPatentin 3.0 <210> 1 <211> 1413 <212> DNA <213> Staphylococcus aureus <400> 1 atgccgtcgg ttaggacata cagtcaagct attagttatc ttaaaagttt agagggtaag 60 gcgtggaatc cagacaatgc atttggatgt caatgcttcg atactgctaa ccaatattgg 120 ctttacttat ttaatcacag gttgaaaggt gtgggcgctg cagacattcc aacatggaat 180 gatttcacta acgaggcaac cgtttacgaa aatactgtgt cgtttcaagc attgcctggc 240 gatgtcgtta tttttaaccg taattatggt ggtggttatg gtcatgtagg tattgtaata 300 agcgctacgt tagattctat aactatttta gagcagaact ggctaggcgg tgcttactgg 360 agtccaccag aagttactac aagacgcaca cacggctacg acttccctat gtggtttatc 420 cgtccattct acgcaaaaga aacgaccgct aataagctaa gaagcgcagt gaagccagtt 480 aaacaagata agttatcaaa aggtaaaaaa atcatgcttg tggctggtca tggtattggt 540 gcatactcta acgaccagg tgccgttgcg aatggagaaa acgaaagaga ttttaaccgt 600 aaaaatatta tacctagagt gaaaaagtat cttgagtcag taggcaacac agtattgtta 660 tacggtggca actcgatgaa tcaagattta tatcaagata cattgtacgg tcaacgtgtt 720 ggaaactata aagattatgg catgtactgg attaaaagtg aagtcaaacc ggatgcaatc 780 atagagtttc atttagattc tgctagccca caagcaagtg gcgggcatgt aatcattagc 840 gatcgtttcc cagctgatga cattgacaag gcattaagta gtgcattaga taaaacagtg 900 ggtaaaataa gaggtgtgac acctagaggg gatttattga acgctaacgt gtctgctgat 960 cttaatctta attatcgttt aatcgaatta ggttttatca catctacgaa agatttaaac 1020 tacattaaaa acaatttaga cagcttcacg aagcggattg ctgaagccat taacggcaga 1080 caaattgatg cgccaagtag taagccaagc gctgacaaaa taacatggaa ttggaaaggc 1140 gtattttatc ctaatccaga aaaagctata agagtcagaa aaacagctgg attaaccggc 1200 acagtcgttg aagaagattc atggctatac acaaaagatg attgggtaaa attcgaccaa 1260 gtcattaaaa aagatggcta ctggtggatt agattcaaat atcaacgtga gggctctagt 1320 actaacaatt tctattgtgc agtgtgtaga attactgata aggaacaaaa gattaaaaat 1380 gaaaaatatt ggggcacgat tgagtgggct taa 1413 <210> 2 <211> 470 <212> PRT <213> Staphylococcus aureus <400> 2 Met Pro Ser Val Arg Thr Tyr Ser Gln Ala Ser Ser Tyr Leu Lys Ser 1 5 10 15 Leu Glu Gly Lys Ala Trp Asn Pro Asp Asn Ala Phe Gly Cys Gln Cys 20 25 30 Phe Asp Thr Ala Asn Gln Tyr Trp Leu Tyr Leu Phe Asn His Arg Leu 35 40 45 Lys Gly Val Gly Ala Ala Asp Ile Pro Thr Trp Asn Asp Phe Thr Asn 50 55 60 Glu Ala Thr Val Tyr Glu Asn Thr Val Ser Phe Gln Ala Leu Pro Gly 65 70 75 80 Asp Val Valle Phe Asn Arg Asn Tyr Gly Gly Gly Tyr Gly His Val 85 90 95 Gly Ile Val Ile Ser Ala Thr Leu Asp Ser Ile Thr Ile Leu Glu Gln 100 105 110 Asn Trp Leu Gly Gly Ala Tyr Trp Ser Pro Pro Glu Val Thr Thr Arg 115 120 125 Arg Thr His Gly Tyr Asp Phe Pro Met Trp Phe Ile Arg Pro Phe Tyr 130 135 140 Ala Lys Glu Thr Thr Ala Asn Lys Leu Arg Ser Ala Val Lys Pro Val 145 150 155 160 Lys Gln Asp Lys Leu Ser Lys Gly Lys Lys Ile Met Leu Val Ala Gly 165 170 175 His Gly Ile Gly Aly Tyr Ser Asn Asp Pro Gly Ala Val Ala Asn Gly 180 185 190 Glu Asn Glu Arg Asp Phe Asn Arg Lys Asn Ile Ile Pro Arg Val Lys 195 200 205 Lys Tyr Leu Glu Ser Val Gly Asn Thr Val Leu Leu Tyr Gly Gly Asn 210 215 220 Ser Met Asn Gln Asp Leu Tyr Gln Asp Thr Leu Tyr Gly Gln Arg Val 225 230 235 240 Gly Asn Tyr Lys Asp Tyr Gly Met Tyr Trp Ile Lys Ser Glu Val Lys 245 250 255 Pro Asp Ile Ile Glu Phe His Leu Asp Ser Ala Ser Pro Gln Ala 260 265 270 Ser Gly Gly His Val Ile Ile Ser Asp Arg Phe Pro Ala Asp Asp Ile 275 280 285 Asp Lys Ala Leu Ser Ser Ala Leu Asp Lys Thr Val Gly Lys Ile Arg 290 295 300 Gly Val Thr Pro Arg Gly Asp Leu Leu Asn Ala Asn Val Ser Ala Asp 305 310 315 320 Leu Asn Leu Asn Tyr Arg Leu Ile Glu Leu Gly Phe Ile Thr Ser Thr 325 330 335 Lys Asp Leu Asn Tyr Ile Lys Asn Asn Leu Asp Ser Phe Thr Lys Arg 340 345 350 Ile Ala Glu Ala Ile Asn Gly Arg Gln Ile Asp Ala Pro Ser Ser Lys 355 360 365 Pro Ser Ala Asp Lys Ile Thr Trp Asn Trp Lys Gly Val Phe Tyr Pro 370 375 380 Asn Pro Glu Lys Ala Ile Arg Val Arg Lys Thr Ala Gly Leu Thr Gly 385 390 395 400 Thr Val Glu Glu Asp Ser Trp Leu Tyr Thr Lys Asp Asp Trp Val 405 410 415 Lys Phe Asp Gln Val Ile Lys Lys Asp Gly Tyr Trp Trp Ile Arg Phe 420 425 430 Lys Tyr Gln Arg Glu Gly Ser Ser Thr Asn Asn Phe Tyr Cys Ala Val 435 440 445 Cys Arg Ile Thr Asp Lys Glu Gln Lys Ile Lys Asn Glu Lys Tyr Trp 450 455 460 Gly Thr Ile Glu Trp Ala 465 470
Claims (6)
스타필로코커스 아우레우스(Staphylococcus aureus)에 대하여 사멸효과가 있는 것을 특징으로 하는 세균 사멸용 조성물.
Carvacrol, cinnamaldehyde and thymol and endocrine LysSA97 having the amino acid sequence of SEQ ID NO: 2,
Wherein the composition has a killing effect against Staphylococcus aureus .
스타필로코커스 아우레우스(Staphylococcus aureus)에 대하여 사멸효과가 있는 것을 특징으로 하는 식품 첨가제.
Carvacrol, cinnamaldehyde and thymol and endocrine LysSA97 having the amino acid sequence of SEQ ID NO: 2,
A food additive characterized by a killing effect against Staphylococcus aureus .
상기 식품은,
스타필로코커스 아우레우스(Staphylococcus aureus)에 오염되기 쉬운 것임을 특징으로 하는 식품 첨가제.
The method of claim 3,
The food,
A food additive characterized by being susceptible to contamination by Staphylococcus aureus .
스타필로코커스 아우레우스(Staphylococcus aureus)에 대하여 사멸효과가 있는 것을 특징으로 하는 식품.
Carvacrol, cinnamaldehyde and thymol and endocrine LysSA97 having the amino acid sequence of SEQ ID NO: 2,
A food characterized by a killing effect against Staphylococcus aureus .
상기 식품은,
스타필로코커스 아우레우스(Staphylococcus aureus)에 오염되기 쉬운 것임을 특징으로 하는 식품.
6. The method of claim 5,
The food,
A food characterized by being susceptible to staphylococcus aureus .
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020160113589A KR101818499B1 (en) | 2016-09-05 | 2016-09-05 | Antibiotic composition with novel endolysin LysSA97 from Staphylococcus aureus bacteriophage and compound from essential oil |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020160113589A KR101818499B1 (en) | 2016-09-05 | 2016-09-05 | Antibiotic composition with novel endolysin LysSA97 from Staphylococcus aureus bacteriophage and compound from essential oil |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR101818499B1 true KR101818499B1 (en) | 2018-01-15 |
Family
ID=61001174
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020160113589A KR101818499B1 (en) | 2016-09-05 | 2016-09-05 | Antibiotic composition with novel endolysin LysSA97 from Staphylococcus aureus bacteriophage and compound from essential oil |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101818499B1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102097128B1 (en) | 2019-06-19 | 2020-04-06 | 서울대학교산학협력단 | Chimeric endolysin Lys109 with antimicrobial activity against Staphylococcus aureus |
| CN114773761A (en) * | 2022-03-29 | 2022-07-22 | 仲恺农业工程学院 | Antibacterial super absorbent resin and preparation method thereof |
-
2016
- 2016-09-05 KR KR1020160113589A patent/KR101818499B1/en active IP Right Grant
Non-Patent Citations (2)
| Title |
|---|
| Journal of Medical Microbiology, 2007, vol 56, pp. 519-523. |
| Letters in Applied Microbiology, 2002, vol 35, pp. 390-394. |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102097128B1 (en) | 2019-06-19 | 2020-04-06 | 서울대학교산학협력단 | Chimeric endolysin Lys109 with antimicrobial activity against Staphylococcus aureus |
| US11827912B2 (en) | 2019-06-19 | 2023-11-28 | Seoul National University R&Db Foundation | Chimeric endolysin LYS109 with antimicrobial activity against staphylococcus aureus |
| CN114773761A (en) * | 2022-03-29 | 2022-07-22 | 仲恺农业工程学院 | Antibacterial super absorbent resin and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR0145738B1 (en) | Novel bacteriocin compositions for use as enhanced broad range bactericides nd method of preventing and treating infelction | |
| Sharahi et al. | Advanced strategies for combating bacterial biofilms | |
| Łusiak-Szelachowska et al. | Bacteriophages and lysins in biofilm control | |
| FI98880C (en) | Lanthionine-Containing Bacteriocin Compositions for Use as Enhanced Extensive Bactericides | |
| Rukayadi et al. | In vitro antibacterial activity of panduratin A against enterococci clinical isolates | |
| EP3795169B1 (en) | Bacteriophage-derived recombinant protein having antimicrobial activity against pathogenic gram-negative bacteria | |
| Fan et al. | Antibacterial activity of the recombinant antimicrobial peptide Ib-AMP4 from Impatiens balsamina and its synergy with other antimicrobial agents against drug resistant bacteria | |
| Bennett et al. | Efficacy of bacteriocin-based formula for reducing staphylococci, streptococci, and total bacterial counts on teat skin of dairy cows | |
| KR101818499B1 (en) | Antibiotic composition with novel endolysin LysSA97 from Staphylococcus aureus bacteriophage and compound from essential oil | |
| Appendini et al. | Antimicrobial activity of a 14-residue synthetic peptide against foodborne microorganisms | |
| Yin et al. | Antibiofilm efficacy of peptide 1018 against Listeria monocytogenes and shiga toxigenic Escherichia coli on equipment surfaces | |
| US11827912B2 (en) | Chimeric endolysin LYS109 with antimicrobial activity against staphylococcus aureus | |
| KR102046139B1 (en) | Natural Antibacterial Compositions Containing Xanthorrhizol | |
| CN101926830A (en) | Antibacterial agent | |
| Chang et al. | Design and Antibacterial Mechanism of Peptides Derived from Sakacin P | |
| KR102503309B1 (en) | Antimicrobial composition containing peptides isolated from hermetia illucens larva extract | |
| Beier et al. | Disinfectants (biocides) used in animal production: antimicrobial resistance considerations | |
| KR101263396B1 (en) | Novel bacteriocin from Bacillus cereus ATCC 13061 and antibiotic composition thereof | |
| Madras-Majewska | Selected mechanisms of the antimicrobial effect of honey in the aspect of drug resistance of bacteria. | |
| Oliveira et al. | Antibacterial Alternatives in the Scope of One Health | |
| Fette | Pre-exposure of Escherichia coli and Staphylococcus aureus to sub-bactericidal concentrations of benzalkonium chloride and its effect on low-level antimicrobial resistance | |
| Turhal et al. | Alternative Approaches to Antimicrobials | |
| Çağmel Turhal et al. | Alternative Approaches to Antimicrobials | |
| Baliga et al. | Bacteriophage Endolysins–Alternative to Antibiotics | |
| CN104523544A (en) | Medical disinfectant hand lotion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |